Hepatitis B Surface Antibody (HBsAb) Interpretation
An anti-HBs level ≥10 mIU/mL indicates protective immunity against hepatitis B virus infection, and immunocompetent individuals with this level after completing the primary vaccine series have long-term protection and do not need further periodic testing or booster doses. 1
Understanding the Protective Threshold
The critical cutoff of ≥10 mIU/mL represents the established correlate of vaccine-induced protection. This threshold should be measured using a quantitative method (such as ELISA) that allows detection of this protective concentration 1. However, it's important to note that different assays have varying cutoff values, so you should refer to the specific test's package insert for accurate interpretation 1.
Clinical Significance by Population
For Immunocompetent Individuals
- Anti-HBs ≥10 mIU/mL: These persons are considered immune and have long-term protection. No further periodic testing or booster doses are needed 1
- Anti-HBs <10 mIU/mL after primary series: These individuals should be revaccinated with a complete second series, followed by repeat testing 1-2 months after the final dose 1
For Healthcare Workers (HCP)
Testing should be performed 1-2 months after the final vaccine dose to document immunity status for future occupational exposures 1. For HCP with anti-HBs <10 mIU/mL:
- Give one additional vaccine dose
- Retest 1-2 months later
- If still <10 mIU/mL, complete a second full series (typically 6 doses total)
- Retest 1-2 months after final dose 1
HCP with documented anti-HBs ≥10 mIU/mL require no postexposure prophylaxis after HBV exposure, regardless of source patient status 1.
For Immunocompromised Populations
These groups require different management:
- Hemodialysis patients: Annual anti-HBs testing with booster when levels decline to <10 mIU/mL 1
- HIV-infected persons, transplant recipients, chemotherapy patients: Consider annual testing and boosters for those with ongoing exposure risk 1
- Infants born to HBsAg-positive mothers: Specific revaccination protocols apply if anti-HBs <10 mIU/mL 1
When Testing is Recommended
Postvaccination serologic testing is NOT routinely recommended for the general population. Testing should be performed only for specific high-risk groups 1:
- Healthcare and public safety workers with blood/body fluid exposure risk
- Hemodialysis patients
- HIV-infected and other immunocompromised persons
- Sex partners of HBsAg-positive persons
Testing should occur 1-2 months after the final vaccine dose 1.
Important Caveats
Waning Antibody Levels
While anti-HBs levels may decline below 10 mIU/mL years after vaccination, this does not necessarily indicate loss of protection. Recent evidence demonstrates that immunologic memory persists even when antibody levels become undetectable 2, 3. A single booster dose typically elicits an anamnestic response in 92% of individuals, confirming intact immune memory 2.
The 2 IU/L Threshold
Research suggests that anti-HBs levels ≥2 IU/mL (though below the 10 mIU/mL protective threshold) are sufficient to predict a prompt response to a booster dose, even years after initial vaccination 4. This indicates preserved immune memory despite low antibody titers.
Non-Responders After Two Complete Series
For individuals with anti-HBs <10 mIU/mL after two complete vaccine series:
- Test for HBsAg to rule out chronic infection 1
- If HBsAg-negative, consider them susceptible to HBV
- Counsel about prevention measures and need for HBIG after known exposures 1
- For occupational exposures, give 2 doses of HBIG one month apart if source is HBsAg-positive 1
Qualitative vs. Quantitative Testing
Qualitative testing alone is insufficient for determining protective immunity. A quantitative assay is required to confirm the ≥10 mIU/mL threshold 1. The distinction matters particularly for healthcare workers and other high-risk populations where documentation of specific antibody levels is essential for exposure management.
Practical Algorithm for Clinical Decision-Making
If anti-HBs ≥10 mIU/mL: No action needed for immunocompetent individuals; document immunity status for HCP
If anti-HBs <10 mIU/mL after primary series:
- Immunocompetent: Revaccinate with second complete series → retest
- HCP: Single booster → retest → if still low, complete second series
- Immunocompromised: Annual monitoring with boosters as needed
If anti-HBs <10 mIU/mL after two complete series: Test HBsAg → if negative, counsel as susceptible; no further vaccination recommended